CLL

Relapsed or Refactory

Criteria to qualify for study: Drug used in study:
  • CD20 positive
  • Must have at least on bi-dimensionally measurable lesion ≥ 1.5 cm.
  • Must have had at least one prior anti­cancer treatment.

SCRI  HEMREF-34

An Open-Label, Phase lb Study of IPI-145 in combination with Bendamustine, Rituximab or Bendamustine/Rituximab in Select Subjects with
Lymphoma or Chronic Lymphocytic Leukemia

 

 

 

 

 

 

Criteria to qualify for study: Drug used in study:
  • Must be CD5, CD19/20, and CD23 positive 
  • Cannot have more than 55% of circulating lymphocytes 
  • Lymphocyte count at diagnosis must be at least 5 x 103/µL

CLL 23 SCRI GP28331 Genentech

A Phase Ib Multicenter Dose-Finding and Safety Study of GDC-0199 and Obinutuzumab in Patients with Relapsed or Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)

 

 

 

 

 

 

Criteria to qualify for study: Drug used in study:
  • Not refractory to ofatumumab
  • Patient not appropriate for treatment or retreatment with purine analog (fludarabine,  pentostatin, cladribine)
  • Must have documentation of cytogentics or FISH for del (17p) - patients are not required to have this mutation
  •  Lymph node at least 1.5 cm
  • Prior allogeneic transplant excluded
  •  CNS disease excludedIPI

CLL 30  SCRI Infinity IPI-145-12

A Phase 3 Study of IPI-145 versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

 

 

 

 

 

 

 

 

Criteria to qualify for study: Drug used in study:
  • Patient cannot have Richter's syndroms
  • Patient cannont have undergone prior allogeneic stem cell transplant
  • Patient cannot be receiving a strong CYP3A4 inhibitor or inducer or a proton pum inhibitor (PPI) or Acid Reducing Agent (ARA)

HEMREF 35 SCRI Portola PRT062070

A Phase I Open-Label, Multi-Dose, Dose Escalation Study of PRT062070 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell Non-Hodgkin Lymphoma (NHL)